Get the Stockscreener App
1.08
10.00%
-0.12
Alx Oncology Holdings Inc stock is traded at $1.08, with a volume of 673.82K.
It is down -10.00% in the last 24 hours and down -41.94% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.20
Open:
$1.2
24h Volume:
673.82K
Relative Volume:
0.62
Market Cap:
$63.29M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.3636
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
-26.03%
1M Performance:
-41.94%
6M Performance:
-57.98%
1Y Performance:
-92.82%
1-Day Range:
$1.08
$1.202
1-Week Range:
$1.08
$1.41
52-Week Range:
$1.08
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.08 | 63.29M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.19 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.89 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
An analyst sees good growth prospects for Alx Oncology Holdings Inc (ALXO) - SETE News
Is it possible to buy Alx Oncology Holdings Inc(ALXO) shares at a good price now? - US Post News
Alx Oncology Holdings Inc (ALXO) receives a Hold rating from Jefferies - Knox Daily
Form S-8Securities to be offered to employees in employee benefit plans - br.ADVFN.com
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 9.4% in January - MarketBeat
ALX Oncology (NASDAQ:ALXO) Price Target Lowered to $2.20 at UBS Group - Defense World
H.C. Wainwright cuts ALX Oncology target to $5, keeps buy rating - MSN
UBS cuts ALX Oncology target to $2.20, keeps Buy rating By Investing.com - Investing.com UK
ALX Oncology (NASDAQ:ALXO) Price Target Cut to $2.20 by Analysts at UBS Group - MarketBeat
ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
Analysts Issue Forecasts for ALX Oncology FY2029 Earnings - MarketBeat
HC Wainwright Comments on ALX Oncology FY2029 Earnings - Defense World
HC Wainwright Has Lowered Expectations for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
ALX Oncology (NASDAQ:ALXO) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
ALX Oncology says evorpacept scores well in Phase II study - The Pharma Letter
Stifel maintains hold on ALX Oncology shares, keeps $3 target By Investing.com - Investing.com UK
ALX Oncology (NASDAQ:ALXO) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
Barclays PLC Grows Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Presents Positive Updated Data from ASPEN-06 - GlobeNewswire
Cantor Fitzgerald Forecasts ALX Oncology FY2025 Earnings - MarketBeat
Cantor Fitzgerald Predicts ALX Oncology FY2025 Earnings - Defense World
Evorpacept shows promise in HER2-positive cancer trial By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ALX Oncology Shares Drop 15% Following Positive Phase 2 - GuruFocus.com
ALX Oncology stock falls 16% amid Phase 2 data update - MSN
Cantor Fitzgerald Weighs in on ALX Oncology FY2025 Earnings - MarketBeat
Evorpacept shows promise in HER2-positive cancer trial - Investing.com India
ALX Oncology Holdings Inc. Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer - Marketscreener.com
ALX Oncology (ALXO) Presents Positive Updated Data from ASPEN-06 Phase 2 Trial - StreetInsider.com
ALX Oncology's Evorpacept Shows Breakthrough 49% Response Rate in Gastric Cancer Trial - StockTitan
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times
ALX Oncology Grants 600,000 Stock Options to New CFO Harish Shantharam at $1.65 - StockTitan
ALX Oncology Announces Further Additions to Leadership Team - GlobeNewswire
ALX Oncology Strengthens Leadership with Key Appointments - TipRanks
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors - The Manila Times
ALX Oncology Strengthens Leadership with Strategic CFO and Board Appointments for Clinical Push - StockTitan
ALX Oncology to Host Virtual Company Event Highlighting - GlobeNewswire
ALX Oncology to Present Crucial Evorpacept Cancer Trial Data at ASCO GI Symposium - StockTitan
ALX Oncology launches new equity incentive plan - MSN
ALX Oncology launches new equity incentive plan By Investing.com - Investing.com South Africa
ALX Oncology Adopts 2025 Inducement Equity Plan - TipRanks
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 9.4% in December - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alx Oncology Holdings Inc Stock (ALXO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
| Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
| Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
613,447 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Sale |
7.90 |
20,000 |
158,076 |
593,447 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 05 '24 |
Sale |
5.50 |
1,823 |
10,025 |
92,113 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 01 '24 |
Sale |
5.82 |
1,373 |
7,989 |
93,936 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):